ReviewNature reviews. Neurology2019
Epidemiology and treatment of multiple sclerosis in elderly populations.
Review in Nature reviews. Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis.European journal of neurology · 2025Pooled it
- ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Pooled it
- Role of Vitamin D in Preventing and Treating Selected Extraskeletal Diseases-An Umbrella Review.Nutrients · 2020Pooled it
- Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.Advances in therapy · 2025Trial
- The effect of education of self-care behaviors on the quality of life and resilience of multiple sclerosis patients.BMC neurology · 2024Trial
- Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.BMC neurology · 2020Trial
- Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.Lancet regional health. Americas · 2026Article
- Unlocking the healing power of Berberine: A promising aid for multiple sclerosis.IBRO neuroscience reports · 2026Review
- The Role of Self-Compassion on Self-Care With the Mediating Role of Illness Perception in Patients With Multiple Sclerosis Referred to Sina Hospital: Based on the Leventhal Model.Brain and behavior · 2026Article
- The Neuroimmune Duality of CD4⁺ T Cells: Drivers of Damage and Repair in the Brain.Molecular neurobiology · 2026Review
- A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis.Neurology and therapy · 2026Article
- Comorbidities in multiple sclerosis: acquired hepatocerebral degeneration mimicking disease progression.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Rethinking prognosis in multiple sclerosis: a multiaxial perspective.Nature reviews. Neurology · 2026Review
- A target trial emulation of the CONFIRM study with an extension to subgroups: an example for relapsing-remitting multiple sclerosis.European journal of epidemiology · 2026Article
- Clinical and functional profile of very old people with multiple sclerosis: a cross-sectional study in the genoa area.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Aging with multiple sclerosis and associated prevalence, incidence, comorbidities and healthcare utilization patterns in a population based study.Scientific reports · 2026Article
- Ultra-low-field MRI for bedside imaging of severe multiple sclerosis.Journal of neurology · 2026Article
- Effects of Aquatic Therapy on Fatigue, Mobility, Physical Function, and Quality of Life in People with Multiple Sclerosis: A Systematic Review and Meta-Analysis.Journal of functional morphology and kinesiology · 2026Review
- Clinical presentation, prognostic factors, and outcomes of meningoencephalitis of unknown origin in older dogs.Journal of veterinary internal medicine · 2026Article
- The burden and trends of late-onset multiple sclerosis, Parkinson's disease, Alzheimer's disease and other dementias among adults aged 55 and older, spanning from 1990 to 2021, with projections through 2050.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing owing to increased longevity of the general population and the availability of effective disease-modifying therapies. However, ageing presents unique challenges in patients with MS largely as a result of their increased frequency of age-related and MS-related comorbidities as well as transition of the disease course from an inflammatory to a neurodegenerative phenotype. Immunosenescence (the weakening of the immune system associated with natural ageing) might be at least partly responsible for this transition, which further complicates disease management. Currently approved therapies for MS are effective in preventing relapse but are not as effective in preventing the accumulation of disability associated with ageing and disease progression. Thus, ageing patients with MS represent a uniquely challenging population that is currently underserved by existing therapeutic regimens. This Review focuses on the epidemiology of MS in ageing patients. Unique considerations relevant to this population are discussed, including the immunology and pathobiology of the complex relationship between ageing and MS, the safety and efficacy of disease-modifying therapies, when discontinuation of treatment might be appropriate and the important role of approaches to support wellness and cognition.
Indexed as
Identifiers
31000816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.